NASDAQ:ZLAB

Zai Lab - ZLAB Stock Forecast, Price & News

$44.88

+0.41 (+0.92%)

(As of 01/27/2023 12:00 AM ET)

Add

Compare

Today's Range: $43.70
▼
$45.09
50-Day Range: $28.97
▼
$48.10
52-Week Range: $20.98
▼
$61.29

Volume: 562,619 shs
Average Volume: 996,863 shs
Market Capitalization: $4.39 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $97.50

Institutional Ownership

Zai Lab MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 117.2% Upside
$97.50 Price Target
Short Interest: Healthy
2.78% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.41
Based on 3 Articles This Week
Insider Trading: Selling Shares
$74,160 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($5.08) to ($3.94) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

484th out of 1,055 stocks

Pharmaceutical Preparations Industry

235th out of 519 stocks

3.5

Analyst's Opinion

Consensus Rating
Zai Lab has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $97.50, Zai Lab has a forecasted upside of 117.2% from its current price of $44.88.
Amount of Analyst Coverage
Zai Lab has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.78% of the outstanding shares of Zai Lab have been sold short.
Short Interest Ratio / Days to Cover
Zai Lab has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Zai Lab has recently increased by 1.12%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Zai Lab does not currently pay a dividend.
Dividend Growth
Zai Lab does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ZLAB.

3.0

News and Social Media Coverage

News Sentiment
Zai Lab has a news sentiment score of 1.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Zai Lab this week, compared to 2 articles on an average week.
Search Interest
Only 11 people have searched for ZLAB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Zai Lab to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Zai Lab insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $74,160.00 in company stock.
Percentage Held by Insiders
Only 6.26% of the stock of Zai Lab is held by insiders.
Percentage Held by Institutions
59.46% of the stock of Zai Lab is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Zai Lab are expected to grow in the coming year, from ($5.08) to ($3.94) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Zai Lab is -7.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Zai Lab is -7.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Zai Lab has a P/B Ratio of 3.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Zai Lab (NASDAQ:ZLAB) Stock

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.

Receive ZLAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter.

ZLAB Stock News Headlines

January 27, 2023 | finance.yahoo.com

Biotech Stocks Reward Shareholders Who Handle The Bumpy Ride

January 18, 2023 | technews.tmcnet.com

Zai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China's National Reimbursement Drug List

January 28, 2023 | Porter & Company (Ad)

The Next Big Crisis Is Here

You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.

January 18, 2023 | msn.com

Paratek/ Zai Lab antibiotic added for reimbursement in China

January 18, 2023 | finance.yahoo.com

Zai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List

January 9, 2023 | benzinga.com

Zai Lab Appoints Michel Vounatsos To Its Board of Directors

January 9, 2023 | finance.yahoo.com

Zai Lab Appoints Michel Vounatsos To Its Board of Directors

January 5, 2023 | seekingalpha.com

Hot Stocks: SI plunges on restructuring; BBBY sets new 52-week low; NVCR, ZLAB skyrocket; LW earnings

January 28, 2023 | Porter & Company (Ad)

The Next Big Crisis Is Here

You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.

January 5, 2023 | finanznachrichten.de

Zai Lab Limited: Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

January 5, 2023 | markets.businessinsider.com

Zai Lab And Novocure Announce LUNAR Study Meets Primary Endpoint

January 5, 2023 | realmoney.thestreet.com

NovoCure Gaps Sharply Higher for a Breakout: How to Play It

January 5, 2023 | msn.com

Novocure, Zai Lab surge as lung cancer therapy meets main goal in late-stage trial

January 5, 2023 | finance.yahoo.com

Novocure, Zai shares rally after lung-cancer treatment meets primary endpoint in study

January 5, 2023 | finance.yahoo.com

This Good News on Cancer Sent 2 Nasdaq Stocks Soaring

January 5, 2023 | finance.yahoo.com

Novocure Stock Surges As Tumor Treating Fields Shows Overall Survival In Lung Cancer Patients

January 5, 2023 | finance.yahoo.com

Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

January 4, 2023 | msn.com

What's Going On With Zai Lab Stock

January 3, 2023 | finance.yahoo.com

Zai Lab Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development

January 1, 2023 | finance.yahoo.com

Companies Like Zai Lab (NASDAQ:ZLAB) Are In A Position To Invest In Growth

December 20, 2022 | finance.yahoo.com

Zai Lab Announces Participation in January Investor Conferences

December 15, 2022 | finance.yahoo.com

Zai Lab Presents Interim Overall Survival Data for ZEJULA® (niraparib) from the NORA Phase 3 Study at the ESMO Virtual Plenary

December 5, 2022 | finance.yahoo.com

Zai Lab Partner Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

November 12, 2022 | finance.yahoo.com

Zai Lab Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags

November 11, 2022 | finance.yahoo.com

Zai Lab Announces Third Quarter 2022 Financial Results and Corporate Updates

November 10, 2022 | seekingalpha.com

Zai Lab Limited (ZLAB) Q3 2022 Earnings Call Transcript

November 9, 2022 | finance.yahoo.com

Zai Lab Announces Third Quarter 2022 Financial Results and Corporate Updates

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ZLAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter.

ZLAB Company Calendar

Last Earnings: 11/09/2022
Today: 1/28/2023
Next Earnings (Estimated): 3/07/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ZLAB
CUSIP: N/A
CIK: 1704292
Web: www.zailaboratory.com
Phone: 862161632588
Fax: 86-21-6163-2570
Employees: 1,951
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $97.50
High Stock Price Forecast: $127.00
Low Stock Price Forecast: $79.00
Forecasted Upside/Downside: +117.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($6.22)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-704,470,000.00
Net Margins: -301.79%
Pretax Margin: -301.41%
Return on Equity: -47.41%
Return on Assets: -40.72%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.78
Quick Ratio: 7.59

Sales & Book Value

Annual Sales: $144.31 million
Price / Sales: 30.45
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $14.31 per share
Price / Book: 3.14

Miscellaneous

Outstanding Shares: 97,910,000
Free Float: 91,780,000
Market Cap: $4.39 billion
Optionable: Optionable
Beta: 1.18

Key Executives

Dr. Ying Du Ph.D. (Age 57)
Founder, Chairperson & CEO
Comp: $1.64M

Mr. Ki Chul Cho (Age 45)
Chief Financial Officer
Comp: $720.97k

Mr. Frazor Titus Edmondson III (Age 57)
Chief Legal Officer & Corp. Sec.
Comp: $829k

Dr. Harald Reinhart M.D. (Age 71)
Pres and Head of Global Devel. for Neuroscience, Autoimmune & Infectious Diseases
Comp: $845.94k

Mr. Joshua L. Smiley (Age 53)
Chief Operating Officer

Dr. Peter Huang Ph.D.
Chief Scientific Officer

Ms. Ann E. Beasley J.D.
Chief Compliance Officer

Dr. Ning Xu M.D. (Age 58)
Exec. VP & Head of Clinical Operations

Dr. Jonathan J. Wang M.B.A. (Age 41)
MBA, Ph.D., Chief Bus. Officer

Dr. James Yan DABT (Age 59)
M.D., Ph.D., Chief Operating Officer of R&D

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ZLAB Stock - Frequently Asked Questions

Should I buy or sell Zai Lab stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZLAB shares.
View ZLAB analyst ratings or view top-rated stocks.
What is Zai Lab's stock price forecast for 2023?: 3 Wall Street analysts have issued 1 year price objectives for Zai Lab's stock. Their ZLAB share price forecasts range from $79.00 to $127.00. On average, they predict the company's share price to reach $97.50 in the next twelve months. This suggests a possible upside of 117.2% from the stock's current price.
View analysts price targets for ZLAB or view top-rated stocks among Wall Street analysts.
How have ZLAB shares performed in 2023?: Zai Lab's stock was trading at $30.70 at the beginning of the year. Since then, ZLAB stock has increased by 46.2% and is now trading at $44.88.
View the best growth stocks for 2023 here.
When is Zai Lab's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our ZLAB earnings forecast.
How were Zai Lab's earnings last quarter?: Zai Lab Limited (NASDAQ:ZLAB) issued its earnings results on Wednesday, November, 9th. The company reported ($1.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by $0.48. The company earned $57.54 million during the quarter, compared to analyst estimates of $53.58 million. Zai Lab had a negative trailing twelve-month return on equity of 47.41% and a negative net margin of 301.79%.
What other stocks do shareholders of Zai Lab own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN).

When did Zai Lab IPO?: (ZLAB) raised $100 million in an IPO on Wednesday, September 20th 2017. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO.
What is Zai Lab's stock symbol?: Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."
Who are Zai Lab's major shareholders?: Zai Lab's stock is owned by a variety of institutional and retail investors. Top institutional investors include Genesis Investment Management LLP (1.52%), M&G Investment Management Ltd. (0.47%) and National Bank of Canada FI (0.04%). Insiders that own company stock include Harald Reinhart, John D Diekman, John D Diekman, Kai-Xian Chen, Peter Wirth, Tao Fu, William Ki Chul Cho, William Lis and Ying Du.
View institutional ownership trends.
How do I buy shares of Zai Lab?: Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Zai Lab's stock price today?: One share of ZLAB stock can currently be purchased for approximately $44.88.
How much money does Zai Lab make?: Zai Lab (NASDAQ:ZLAB) has a market capitalization of $4.39 billion and generates $144.31 million in revenue each year. The company earns $-704,470,000.00 in net income (profit) each year or ($6.22) on an earnings per share basis.
How many employees does Zai Lab have?: The company employs 1,951 workers across the globe.
How can I contact Zai Lab?: Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The official website for the company is www.zailaboratory.com. The company can be reached via phone at 862161632588, via email at jsteier@burnsmc.com, or via fax at 86-21-6163-2570.

This page (NASDAQ:ZLAB) was last updated on 1/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Zai Lab - ZLAB Stock Forecast, Price & News

Zai Lab MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Zai Lab (NASDAQ:ZLAB) Stock

ZLAB Stock News Headlines

ZLAB Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ZLAB Stock - Frequently Asked Questions

Overall MarketRank^™